Search
Cretostimogene grenadenorepvec
go.drugbank.com/drugs/DB05148InvestigationalCG0070 can potentially destroy cancer cells by two different mechanisms: direct cell killing by the virus and immune-mediated cell killing stimulated by GM-CSF.
Ambroxol
go.drugbank.com/drugs/DB06742ApprovedInvestigationalIt stimulates synthesis and release of surfactant by type II pneumocytes. … Surfactants acts as an anti-glue factor by reducing the adhesion of mucus to the bronchial wall, in improving its transport and in providing protection against infection and irritating agents.
Cabazitaxel
go.drugbank.com/drugs/DB06772ApprovedInvestigationalIt was first approved by the FDA on June 17, 2010.[A260421] It was also approved by the EMA on March 17, 2011 [L47381] and Health Canada on December 17, 2019.[L47376]
Lutetium Lu-177 vipivotide tetraxetan
go.drugbank.com/drugs/DB16778ApprovedInvestigational[L43787] In December 2022, lutetium Lu-177 vipivotide tetraxetan was approved by the EMA.[L43787,L45533] … [L41280] Lutetium Lu-177 vipivotide tetraxetan was first approved by the FDA on March 23, 2022 as a treatment for prostate-specific membrane antigen–positive metastatic castration-resistant prostate
Tannic acid
go.drugbank.com/drugs/DB09372ApprovedInvestigationalTannic acid is also taken by mouth and applied directly for bleeding, chronic diarrhea, dysentery, bloody urine, painful joints, persistent coughs, and cancer. … Tannic acid is found in the nutgalls formed by insects on twigs of certain oak trees (Quercus infectoria and other Quercus species). It is removed and used as medicine.
Progesterone
go.drugbank.com/drugs/DB00396ApprovedInvestigationalVet approvedProgesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to...
Omaveloxolone
go.drugbank.com/drugs/DB12513ApprovedInvestigational[A257529] In February 2023, omaveloxolone was approved by the FDA for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.
Interferon beta-1a
go.drugbank.com/drugs/DB00060ApprovedInvestigationalIt is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced.
Cixutumumab
go.drugbank.com/drugs/DB12250InvestigationalCixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of tumour types.
Pozelimab
go.drugbank.com/drugs/DB15218ApprovedInvestigational[L47850] In August 18, 2023, pozelimab was approved by the FDA for the treatment of CHAPLE disease. It is currently the only treatment explicitly indicated for CHAPLE disease.[L47875]